I think it's amusing watching some people (esp on
Post# of 72436
![Avatar](/images/ProfileImages/1207987678_3042_Picture 5.jpg)
The fact is that no one knows what could happen with successful P2's/P3's.
I still look at Intercept Pharma back in 2014/Jan and what happened when a P2 interim analysis was so good they ended the trial.
Here's a link that I found interesting on that as well as Galt's approach.
Don't think it could happen to CTIX ? Think again.
http://secfilings.com/News.aspx?title=leading...p;naid=703
Kelt
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)